PRE-ECLAMPSIA PREDICTOR sFLT-1PIGF RATIO PANEL Test
Test Name: PRE-ECLAMPSIA PREDICTOR sFLT-1PIGF RATIO PANEL Test
Components: PLGF, sFLT-1, PIGF RATIO
Price: 700.0 AED
Sample Condition: 2 mL (1 mL min.) serum from 1 SST. Ship refrigerated or frozen.
Report Delivery: SampleTue / Thu /Sat by 9 am; Report Same Day
Method: ECLIA
Test type: Pre-eclampsia
Doctor: Gynecologist
Test Department: Pre Test Information
No special preparation required
Test Details
The PRE-ECLAMPSIA PREDICTOR (sFLT-1:PIGF RATIO) PANEL test is a diagnostic tool used to assess the risk of developing pre-eclampsia during pregnancy. Pre-eclampsia is a serious condition characterized by high blood pressure and damage to organs such as the liver and kidneys. It can be life-threatening for both the mother and the baby if left untreated.
The test measures the ratio of two proteins in the blood: soluble fms-like tyrosine kinase-1 (sFLT-1) and placental growth factor (PIGF). In women with pre-eclampsia, the levels of sFLT-1 are increased, while the levels of PIGF are decreased. By comparing the ratio of these proteins, the test can provide an indication of the likelihood of developing pre-eclampsia.
The test is typically performed around the 20th week of pregnancy and can help healthcare providers identify women who may require closer monitoring or early intervention to prevent or manage pre-eclampsia. Early detection and management of pre-eclampsia can significantly improve outcomes for both the mother and the baby.
It is important to note that the PRE-ECLAMPSIA PREDICTOR (sFLT-1:PIGF RATIO) PANEL test is just one tool in the assessment of pre-eclampsia risk and should be used in conjunction with other clinical evaluations and tests. It is not a definitive diagnosis of pre-eclampsia but rather a tool to aid in risk assessment and decision-making.
Test Name | PRE-ECLAMPSIA PREDICTOR sFLT-1PIGF RATIO PANEL Test |
---|---|
Components | *PLGF*sFLT-1*PIGF RATIO |
Price | 700.0 AED |
Sample Condition | 2 mL (1 mL min.) serum from 1 SST. Ship refrigerated or frozen. |
Report Delivery | SampleTue / Thu /Sat by 9 am; Report Same Day |
Method | ECLIA |
Test type | Pre-eclampsia |
Doctor | Gynecologist |
Test Department: | |
Pre Test Information | No special preparation required |
Test Details |
The PRE-ECLAMPSIA PREDICTOR (sFLT-1:PIGF RATIO) PANEL test is a diagnostic tool used to assess the risk of developing pre-eclampsia during pregnancy. Pre-eclampsia is a serious condition characterized by high blood pressure and damage to organs such as the liver and kidneys. It can be life-threatening for both the mother and the baby if left untreated. The test measures the ratio of two proteins in the blood: soluble fms-like tyrosine kinase-1 (sFLT-1) and placental growth factor (PIGF). In women with pre-eclampsia, the levels of sFLT-1 are increased, while the levels of PIGF are decreased. By comparing the ratio of these proteins, the test can provide an indication of the likelihood of developing pre-eclampsia. The test is typically performed around the 20th week of pregnancy and can help healthcare providers identify women who may require closer monitoring or early intervention to prevent or manage pre-eclampsia. Early detection and management of pre-eclampsia can significantly improve outcomes for both the mother and the baby. It is important to note that the PRE-ECLAMPSIA PREDICTOR (sFLT-1:PIGF RATIO) PANEL test is just one tool in the assessment of pre-eclampsia risk and should be used in conjunction with other clinical evaluations and tests. It is not a definitive diagnosis of pre-eclampsia but rather a tool to aid in risk assessment and decision-making. |